{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"Progression is defined as relapse","groups":[{"description":"Treosulfan IV over 2 hours on days -6 to -4 and fludarabine phosphate IV over 30 minutes on days -6 to -2.","id":"OG000","title":"Arm A (Treosulfan, Fludarabine Phosphate)"},{"description":"Treosulfan and fludarabine phosphate as in Arm A and undergo low-dose TBI on day 0.","id":"OG001","title":"Arm B (Treosulfan, Fludarabine Phosphate, TBI)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At 6 months post-transplant","title":"Number of Participants That Did Not Progress Within 6 Months","type":"PRIMARY","unitOfMeasure":"Participants"}